The FDA has granted approval to a second biosimilar to infliximab (Remicade, Johnson & Johnson). Infliximab-abda (Renflexis), an intravenous infusion developed by Samsung Bioepsis/Merck, has been approved for multiple indications.
This tumor necrosis factor (TNF) inhibitor has been indicated for various inflammatory conditions, including Crohn’s disease (adult and pediatric), ulcerative colitis, rheumatoid arthritis (combined with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
"Once Renflexis hits the market, it will be the first time we will see competition between 2 biosimilars, Inflectra and Renflexis, along with the reference product Remicade," said Brian Lehman, MBA, MHA, RPh, who is a manager of pharmacy benefits and policy in Columbus, Ohio. Lehman, who also serves on the editorial board of The Center for Biosimilars, added that Renflexis offers another important option for patients and providers in the treatment of serious inflammatory diseases.
The most common adverse reactions for infliximab-abda include infections, infusion-related reactions, headache, and abdominal pain, and its use is contraindicated with anakinra or abatacept. The label also indicates that the drug has not been evaluated in children under 6 years diagnosed with ulcerative colitis or Crohn’s disease.
Infliximab-abda will be available in single-dose vials containing 100 mg of lyophilized drug for a final reconstitution volume of 10 mL.
The first biosimilar to infliximab, infliximab-dyyb (Inflectra, Pfizer), was approved in November 2016. While Pfizer struggled for a while falling the launch of the drug, the company’s biosimilar revenues grew by 48% a year later—fourth quarter sales from Inflectra touched $61 million in 2016 (up from $30 million a year ago) despite the fact that the drug is being sold at only a 15% discount to Remicade.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.